Background: Oral anticoagulants are prescribed in non-valvular atrial fibrillation for stroke prevention; however, little is known about the current management of anticoagulation in France, particularly given the availability of non-vitamin K antagonist oral anticoagulants in recent years. Aims: To describe the characteristics of patients prescribed oral anticoagulants, and assess treatment persistence in French primary care. Methods: We conducted a cohort study of patients with non-valvular atrial fibrillation, who were newly prescribed oral anticoagulants between 1 January 2014 and 31 January 2016, using French primary care data (IMS Longitudinal Patient Database). Adjusting for baseline characteristics, risk of non-persistence (switch or discontinuation) was compared using Cox regression. Results: Of 4111 patients, 1710 were newly prescribed vitamin K antagonists, 1257 rivaroxaban, 744 apixaban and 400 dabigatran. The median age was 76 years, and 57.5% were male. History of hypertension was the most common co-morbidity (68.1%). Compared with vitamin K antagonists, non-persistence was higher with rivaroxaban (hazard ratio: 1.28; 95% confidence interval: 1.13–1.45) and dabigatran (hazard ratio: 1.42; 95% confidence interval: 1.20–1.69) and similar with apixaban (hazard ratio: 1.12; 95% confidence interval: 0.96–1.32). Conclusions: Non-persistence (treatment discontinuation or switch) with vitamin K antagonists was lower than with rivaroxaban and dabigatran in French primary care; however, non-persistence with the newest drug, apixaban, was similar to vitamin K antagonists. Larger studies with longer follow-up are needed to support these findings. This study is registered on ClinicalTrials.gov (NCT02488421).
Collings, S. L., Vannier-Moreau, V., Johnson, M. E., Stynes, G., Lefèvre, C., Maguire, A., … Fauchier, L. (2018). Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France. Archives of Cardiovascular Diseases, 111(5), 370–379. https://doi.org/10.1016/j.acvd.2017.10.003